Anti-Coagulants - Austria

Austria

The Anti-Coagulants market in Austria is expected to witness a significant increase in revenue, with projections indicating a value of US$107.60m in 2024.
This growth is anticipated to continue at an annual growth rate (CAGR 2024-2029) of 7.64%, culminating in a market volume of US$155.50m by 2029.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue in the Anti-Coagulants market, with an estimated value of US$16,740.00m in 2024.
Austria's anti-coagulant market is witnessing a surge in demand for direct oral anticoagulants, driven by their ease of use and improved patient outcomes.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Austria is showing promising growth in recent years.

Customer preferences: Patients in Austria are increasingly opting for anti-coagulant drugs due to the rising incidence of thrombosis and stroke. Additionally, the aging population in the country is also contributing to the growth of the market as older individuals are more prone to such conditions.

Trends in the market: The market for anti-coagulants in Austria is witnessing a shift from traditional blood thinners towards newer oral anticoagulants (NOACs). This is due to the advantages offered by NOACs such as lower risk of bleeding and fewer drug interactions. Furthermore, there is also a trend towards personalized treatment in the market, with doctors tailoring the dosage and type of anti-coagulant based on the patient's medical history and risk factors.

Local special circumstances: The healthcare system in Austria is highly developed, with universal coverage and a strong emphasis on preventive care. This has led to a higher awareness among patients regarding the importance of managing cardiovascular risk factors, including the use of anti-coagulants. Additionally, the country has a well-established pharmaceutical industry, with several local and multinational players operating in the market.

Underlying macroeconomic factors: Austria has a stable and prosperous economy, with a high standard of living and a well-educated population. This has led to a higher demand for quality healthcare services, including the use of advanced drugs such as anti-coagulants. Furthermore, the country has a favorable regulatory environment for the pharmaceutical industry, with a transparent and efficient approval process for new drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.